

Candidate development of individualized cancer vaccine for the non-Hodgkin Lymphoma

Progeneer Inc.



ONCOLOGY	Candidate
Product Type	Biological-Protein(vaccine: recombinant protein with adjuvant)
Indication	Non-Hodgkin Lymphoma
Target	Non-Hodgkin Lymphoma
MoA(Mechanism of Action)	Anti-tumor response through cellular & humoral immunity induced by therapeutic vaccine
Competitiveness	<ul style="list-style-type: none"> - Antigen expression: Proprietary in-vitro protein expression platform enables rapid and cost-effective production of individualized antigen in 4 weeks - Adjuvant: Proprietary adjuvant technology induces strong cellular response - Bioinformatics: Identify mutant BCR sequence from NGS data in each patient thereby providing truly individualized treatment
Development Stage	Candidate
Route of Administration	Subcutaneous Injection